MERCK Stock Quote
$57.97 
Change:
0.13 %Chge:
0.22% Vol:
894,283
End Of Day Prices
High: 58.26 | Low: 57.815 | Open: 57.88 | Close: 57.97
52 Wk High: 63.62 | 52 Wk Low: 53.11 | Todays Pivot: 58.02
Sector: Healthcare and Pharmaceuticals
Merck Company Profile
Merck & Co (MRK) is a global pharmaceutical giant that manufactures key health products for human and animal health. They are the second largest company worldwide, as measured by market share. Grossing over $27 billion dollars annually, Merck are well known for producing leading scientific research and powerful pharmaceutical products. Since merging with Schering-Plough in 2009, the company has combined product lines for what they term is a “stronger pipeline”
» Read More About Merck
MRK Chart
You need Flash Player to see the chart, please download from the link below
Related Healthcare and Pharmaceuticals Companies
Above is a small selection of related companies to Merck which compete alongside MRK within the Healthcare and Pharmaceuticals sector.
Online News For Merck
|
Merck to cut 120 employees in Lexington at newly acquired Cubist - Boston Business Journal (blog)
Fri, 06 Mar 2015 12:55Lainie Keller, director of global communications at Merck, told the Boston Business Journal that the "difficult decision" came as Merck was reviewing its assets, which includes a 450-employee research center in Kendall Square and a Boston-based ...
|
|
Merck Strips Out Cubist - Corante
Fri, 06 Mar 2015 13:58Remember Merck buying Cubist? And the problems that immediately came up around the company's patent estate? Merck stuck to their decision, with lots of talk about how they were committed to it no matter what, but one always had to wonder what the ...
|
|
Merck and Eisai link up on anti-PD-1 combinations - PMLiVE
Fri, 06 Mar 2015 11:10Merck_Co_logo Merck & Co has signed another deal to explore a combination of its PD-1 inhibitor Keytruda with other anticancer drugs, this time forging an alliance with Japan's Eisai. Under the terms of the agreement, Keytruda (pembrolizumab) will be ...
|
|
Germany's Merck Cautious After Deal Spree - Wall Street Journal
Tue, 03 Mar 2015 09:20FRANKFURT—Germany's Merck KGaA forecasts little or no improvement in earnings this year after a slight drop in fourth-quarter net profit, with stiff competition for its blockbuster multiple-sclerosis treatment and higher research spending likely to ...
|
|
Merck touts a bright future in biosimilars with a stable of would-be blockbusters - FierceBiotech
Tue, 03 Mar 2015 16:36Merck ($MRK) may trail the first movers in the coming onslaught of blockbuster biosimilars, but the pharma giant is heralding a crop of late-stage copycat treatments it believes can snag a share of the soon-to-boom market. Presenting at this week's ...
|
|
Merck's Partnership With NGM Is A Bold Move - Forbes
Tue, 03 Mar 2015 13:43Last week Merck signed a deal with NGM Biopharmaceuticals, which we believe is a bold and a long-term move. Under the multi-year agreement, Merck will make a payment of $95 million to NGM to establish a co-development alliance and acquire another ...
|
Want To Add This Quote To Your Site?
With our stock widgets you can add a Merck quote to your website to keep your users up to date with the market. We have a variety of different styled widgets for MRK to choose from. Visit here to build your stock quote widget »
